Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory T Moore

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Journal of Crohn'S & Colitis|December 19, 2013
Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: a cross-sectional, observational studyPeter R Gibson, Carolynne Vaizey, Christopher M Black, et al.
The Lancet. Gastroenterology & Hepatology|December 10, 2021
Intensive drug therapy versus standard drug therapy for symptomatic intestinal Crohn's disease strictures (STRIDENT): an open-label, single-centre, randomised controlled trialJulien D Schulberg, Emily K Wright, Bronte A Holt, et al.
Alimentary Pharmacology & Therapeutics|September 27, 2020
Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposureEmma Flanagan, Peter R Gibson, Emily K Wright, et al.
Gastroenterology|March 27, 2025
Active Inflammatory Bowel Disease on Intestinal Ultrasound During Pregnancy Is Associated With an Increased Risk of Adverse Pregnancy and Neonatal Outcomes Independent of Clinical and Biochemical Disease ActivityRalley E Prentice, Emma K Flanagan, Emily K Wright, et al.
BMJ Open|July 20, 2024
Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease (DISCUS-IBD): protocol for a multicentre randomised controlled trialRobert D Little, Jo McKenzie, Ashish Srinivasan, et al.
Internal Medicine Journal|September 5, 2024
6-Thioguanine nucleotide levels are associated with infliximab but not adalimumab levels in inflammatory bowel disease patients on combination therapyNatalie Yu, Tanya Lee, Daniel Tassone, et al.
Inflammatory Bowel Diseases|December 3, 2025
Low Rates of Surgical Recurrence Following Ileocolic Resections for Crohn's Disease in the Biologic EraHugh L Giddings, Kheng-Seong Ng, Michael J Solomon, et al.
Inflammatory Bowel Diseases|May 30, 2019
Anti-TNF Therapy in Pregnant Women With Inflammatory Bowel Disease: Effects of Therapeutic Strategies on Disease Behavior and Birth OutcomesMette Julsgaard, Christian L Hvas, Richard B Gearry, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Journal of Crohn'S & Colitis|December 19, 2013
Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: a cross-sectional, observational studyPeter R Gibson, Carolynne Vaizey, Christopher M Black, et al.
The Lancet. Gastroenterology & Hepatology|December 10, 2021
Intensive drug therapy versus standard drug therapy for symptomatic intestinal Crohn's disease strictures (STRIDENT): an open-label, single-centre, randomised controlled trialJulien D Schulberg, Emily K Wright, Bronte A Holt, et al.
Alimentary Pharmacology & Therapeutics|September 27, 2020
Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposureEmma Flanagan, Peter R Gibson, Emily K Wright, et al.
Gastroenterology|March 27, 2025
Active Inflammatory Bowel Disease on Intestinal Ultrasound During Pregnancy Is Associated With an Increased Risk of Adverse Pregnancy and Neonatal Outcomes Independent of Clinical and Biochemical Disease ActivityRalley E Prentice, Emma K Flanagan, Emily K Wright, et al.
BMJ Open|July 20, 2024
Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease (DISCUS-IBD): protocol for a multicentre randomised controlled trialRobert D Little, Jo McKenzie, Ashish Srinivasan, et al.
Internal Medicine Journal|September 5, 2024
6-Thioguanine nucleotide levels are associated with infliximab but not adalimumab levels in inflammatory bowel disease patients on combination therapyNatalie Yu, Tanya Lee, Daniel Tassone, et al.
Inflammatory Bowel Diseases|December 3, 2025
Low Rates of Surgical Recurrence Following Ileocolic Resections for Crohn's Disease in the Biologic EraHugh L Giddings, Kheng-Seong Ng, Michael J Solomon, et al.
Inflammatory Bowel Diseases|May 30, 2019
Anti-TNF Therapy in Pregnant Women With Inflammatory Bowel Disease: Effects of Therapeutic Strategies on Disease Behavior and Birth OutcomesMette Julsgaard, Christian L Hvas, Richard B Gearry, et al.
Pageof 4